These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15569985)

  • 21. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
    Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
    Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
    de La Motte Rouge T; Galluzzi L; Olaussen KA; Zermati Y; Tasdemir E; Robert T; Ripoche H; Lazar V; Dessen P; Harper F; Pierron G; Pinna G; Araujo N; Harel-Belan A; Armand JP; Wong TW; Soria JC; Kroemer G
    Cancer Res; 2007 Jul; 67(13):6253-62. PubMed ID: 17616683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
    Suzui M; Masuda M; Lim JT; Albanese C; Pestell RG; Weinstein IB
    Cancer Res; 2002 Jul; 62(14):3997-4006. PubMed ID: 12124333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines.
    Joe AK; Liu H; Suzui M; Vural ME; Xiao D; Weinstein IB
    Clin Cancer Res; 2002 Mar; 8(3):893-903. PubMed ID: 11895924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2005 Nov; 70(11):1568-78. PubMed ID: 16226226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
    Jacobs MA; Wotkowicz C; Baumgart ED; Neto BS; Rieger-Christ KM; Bernier T; Cohen MS; Libertino JA; Summerhayes IC
    J Urol; 2007 Oct; 178(4 Pt 1):1510-4. PubMed ID: 17707060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
    Lassman AB; Rossi MR; Raizer JJ; Abrey LE; Lieberman FS; Grefe CN; Lamborn K; Pao W; Shih AH; Kuhn JG; Wilson R; Nowak NJ; Cowell JK; DeAngelis LM; Wen P; Gilbert MR; Chang S; Yung WA; Prados M; Holland EC
    Clin Cancer Res; 2005 Nov; 11(21):7841-50. PubMed ID: 16278407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
    Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD
    Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy.
    Dragnev KH; Pitha-Rowe I; Ma Y; Petty WJ; Sekula D; Murphy B; Rendi M; Suh N; Desai NB; Sporn MB; Freemantle SJ; Dmitrovsky E
    Clin Cancer Res; 2004 Apr; 10(7):2570-7. PubMed ID: 15073138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
    Jimeno A; Kulesza P; Kincaid E; Bouaroud N; Chan A; Forastiere A; Brahmer J; Clark DP; Hidalgo M
    Cancer Res; 2006 Feb; 66(4):2385-90. PubMed ID: 16489045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer.
    Yang SX; Simon RM; Tan AR; Nguyen D; Swain SM
    Clin Cancer Res; 2005 Sep; 11(17):6226-32. PubMed ID: 16144925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.
    Koyama S; Omura T; Yonezawa A; Imai S; Nakagawa S; Nakagawa T; Yano I; Matsubara K
    PLoS One; 2015; 10(8):e0136176. PubMed ID: 26288223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells.
    Boyle JO; Langenfeld J; Lonardo F; Sekula D; Reczek P; Rusch V; Dawson MI; Dmitrovsky E
    J Natl Cancer Inst; 1999 Feb; 91(4):373-9. PubMed ID: 10050872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.
    Lonardo F; Dragnev KH; Freemantle SJ; Ma Y; Memoli N; Sekula D; Knauth EA; Beebe JS; Dmitrovsky E
    Clin Cancer Res; 2002 Jan; 8(1):54-60. PubMed ID: 11801540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
    Carey KD; Garton AJ; Romero MS; Kahler J; Thomson S; Ross S; Park F; Haley JD; Gibson N; Sliwkowski MX
    Cancer Res; 2006 Aug; 66(16):8163-71. PubMed ID: 16912195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
    Kim JC; Ali MA; Nandi A; Mukhopadhyay P; Choy H; Cao C; Saha D
    Indian J Biochem Biophys; 2005 Dec; 42(6):358-65. PubMed ID: 16955736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repression of cyclin D1 as a target for germ cell tumors.
    Freemantle SJ; Vaseva AV; Ewings KE; Bee T; Krizan KA; Kelley MR; Hattab EM; Memoli VA; Black CC; Spinella MJ; Dmitrovsky E
    Int J Oncol; 2007 Feb; 30(2):333-40. PubMed ID: 17203214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride.
    Kundu S; Sengupta S; Bhattacharyya A
    Inhal Toxicol; 2011 May; 23(6):339-48. PubMed ID: 21605009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.